CAR-T细胞治疗的免疫学后果:感染并发症与免疫重建分析
本研究对52例接受抗CD19或BCMA靶向CAR-T细胞治疗的患者(42例复发/难治性弥漫大B细胞淋巴瘤,10例复发/难治性多发性骨髓瘤)进行1年随访,分析免疫重建与感染并发症。CAR-T治疗后B细胞和T细胞深度耗竭,CD4+ T细胞和CD19+ B细胞再生受损;感染在最初30天更频繁,早期以细菌感染为主,长期随访中转为病毒感染且感染密度下降;严重细胞因子释放综合征与晚发型感染风险升高相关。
要点
- CAR-T治疗后CD4+ T细胞和CD19+ B细胞再生受损。
- 感染在CAR-T输注后最初30天更频繁,早期以细菌感染为主。
- 长期随访中感染转为以病毒为主,严重细胞因子释放综合征与晚发型感染风险升高相关。
核心结论
- CAR-T细胞治疗导致B细胞和T细胞深度耗竭,CD4+ T细胞和CD19+ B细胞再生受损。
- 感染在治疗后最初30天更频繁,早期以细菌感染为主,长期随访转为病毒感染且感染密度下降。
- 严重细胞因子释放综合征与晚发型感染风险升高相关。
研究设计与样本
- 1年随访分析,纳入52例患者,其中42例为复发/难治性弥漫大B细胞淋巴瘤(DLBCL),10例为复发/难治性多发性骨髓瘤(MM)。
- 患者接受抗CD19或B细胞成熟抗原(BCMA)靶向CAR-T细胞治疗,聚焦免疫重建与感染并发症。
主要发现
- CAR-T细胞治疗导致B细胞和T细胞深度耗竭,CD4+ T细胞和CD19+ B细胞再生受损。
- 短期随访中,风险100天内的感染密度在DLBCL患者为1.8,在MM患者为4.6,早期以细菌感染为主。
- 长期随访中转为病毒感染,感染密度在DLBCL患者降至0.1次/100风险日,在MM患者降至0.4次/100风险日。
- 严重细胞因子释放综合征与晚发型感染风险升高相关。
临床怎么用
- 作者认为,在接受CAR-T细胞治疗的患者中,密切监测和预防措施对于降低感染风险及促进免疫恢复具有重要意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in treating relapsed and refractory (R/R) B-cell neoplasms, such as diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Despite its success, the long-term effects and sequelae of CAR T cells on the immune system remain underexplored. This study presents a 1-year follow-up analysis of 52 patients (42 with R/R DLBCL and 10 with R/R MM) treated with anti-CD19- and B-cell maturation antigen-targeted CAR T cells, focusing on immune reconstitution and infectious complications. Our findings reveal that CAR T-cell therapy leads to profound depletion of B and T cells. CD4+ T cells and CD19+ B cells exhibited impaired regeneration after treatment. Infections were more frequent during the first 30 days. In the short-term follow-up, density of infections within 100 days at risk was 1.8 in patients with DLBCL and 4.6 in patients with MM, with bacterial infections predominating in this early period after CAR T-cell infusion. In addition, we observed a shift to viral infections in the long-term follow-up, alongside with a decline in infection density to 0.1 in patients with DLBCL and 0.4 infections per 100 days at risk in patients with MM, respectively. Severe cytokine release syndrome was associated with a higher risk of late-onset infections. These findings highlight the importance of close monitoring and prophylactic measures in patients undergoing CAR T-cell therapy to reduce infection risks and enhance immune recovery.
引用
- Riedel A, Phely L, Hug S, et al. Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution. Blood Adv. 2025. PMID: 40188456. doi:10.1182/bloodadvances.2024015346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。